How Nandrolone Decanoate Affects HDL Cholesterol

Nandrolone decanoate suppresses HDL via androgenic hepatic lipase activation, but through a pathway that is substantially milder than oral 17-alpha-alkylated compounds:

1. Injectable 17-beta-ester, no first-pass hepatic exposure: Unlike oral 17-AA steroids, nandrolone decanoate is an injectable ester that bypasses the liver on first pass. The decanoate ester is cleaved slowly in muscle and adipose tissue, releasing nandrolone gradually into systemic circulation. The liver then processes this much lower, more physiological concentration of androgen, producing far less HTGL stimulation than the concentrated first-pass load from an oral compound.
2. Modest HTGL upregulation: Nandrolone does upregulate hepatic lipase, but the magnitude is substantially lower than that seen with stanozolol or other 17-AA orals. The effect is dose-dependent and becomes more significant only at higher weekly doses.
3. No aromatisation at supraphysiological doses: Nandrolone aromatises minimally compared to testosterone. At moderate doses, the small amount of estrogenic activity provides minimal HDL protection. At higher doses, the androgenic HTGL stimulation dominates with little estrogenic offset.
4. Dose-dependency is the defining feature: Hartgens (2004) demonstrated no significant HDL change at 200 mg/week. Kuipers (1991) documented a 25-27% HDL decline at 100 mg/week in some cohorts. Sattler (2002) found decreases of 8.7-10.6 mg/dL at 300-600 mg/week. The dose-response is real but attenuated compared to other compounds.

At 200 mg/week:

• Minimal to no significant HDL change documented in Hartgens 2004 RCT
• Some individuals may see a mild 5-15% decline depending on background lipid sensitivity

At 100 mg/week:

• Paradoxically, some cohorts (Kuipers 1991) show 25-27% HDL declines at this lower dose, possibly reflecting population-level variation in androgenic sensitivity. This highlights that individual responses vary.

At 300-600 mg/week:

• Decreases of 8.7-10.6 mg/dL documented (Sattler 2002)
• At high bodybuilding doses (400-600 mg/week), a 15-30% HDL reduction is a reasonable expectation

Comparative context: At equivalent weekly doses, nandrolone decanoate produces substantially less HDL suppression than any oral 17-AA compound. This makes it a preferred injectable base for athletes who need to add a compound to testosterone but want to minimise lipid deterioration.

Baseline lipid panel before starting:

• Establish your pre-cycle HDL reference

On cycle:

• Check lipids at week 6-8 (the longer ester and more modest effect means earlier testing is less informative than with faster-acting orals)
• If HDL falls below 30 mg/dL at moderate doses, consider dose reduction

Post-cycle:

• Recheck 6-8 weeks after the last injection (accounting for the decanoate ester's long half-life; the compound is not fully cleared for several weeks after the last dose)

During cycle:

• At moderate doses (200-400 mg/week), standard cardiovascular exercise and omega-3 supplementation is typically sufficient harm reduction
• Avoid adding oral 17-AA compounds to a nandrolone base if HDL protection is a priority; the orals will dominate the lipid picture and negate the relative safety advantage of nandrolone
• Omega-3 fatty acids 2-4 g EPA/DHA daily
• Cardiovascular exercise 150+ minutes per week

Cycle design consideration:

• For bodybuilders concerned about cardiovascular risk, a testosterone and nandrolone stack (without orals) is among the more lipid-conservative compound combinations. Substituting trenbolone for nandrolone significantly worsens the lipid profile.